Atomico leads $56m round for Healx

Global Brain, B-to-V Partners and Intel Capital, the venture capital arm of Intel Corp, also participated in the round. All previous investors, including Balderton Capital and Amadeus Capital Partners, as well as business angel Jonathan Milner, joined the round.

Atomico is currently investing from its Atomico IV fund, which closed on $765m in 2017. Atomico principal Irina Haivas has joined the board of Healx.

The fresh capital will be used to launch a rare-disease treatment accelerator programme and progress into clinical trials.

Previous funding
Amadeus invested £1.5m in Healx in 2016 to fund the company's research activity and enable it to invest in the development of its technology platform.

Balderton led a $10m series-A for the company in July 2018. Existing investor Amadeus Capital also took part in the round alongside angel investor Jonathan Milner, the co-founder and deputy chairperson of biotechnology company Abcam and a non-executive director at equity crowdfunding business Syndicate Room.

Company
Founded in 2014, Cambridge-headquartered Healx combines artificial intelligence, pharmacology research and insights from patient groups to develop new approaches to treating rare diseases. The company employs 51 people, according to LinkedIn.

People
Atomico – Irina Haivas (principal).
Healx – Tim Guilliams (co-founder, CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• United Kingdom
• Atomico
• Balderton Capital
• Corporate Venture
• Amadeus Capital Partners Ltd